This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
🩺 Clinical Context
In the era of the 21st Century Cures Act, the mandate for immediate, unredacted release of pathology and radiology results via patient portals has fundamentally shifted the patient-physician relationship. For the Interventional Pulmonologist, this is particularly high-stakes: patients often view their bronchoscopy biopsy results—which may contain words like “malignancy,” “carcinoma,” or “granulomatous inflammation”—in isolation, often hours or days before they can discuss the findings with their proceduralist. This study evaluates the patient experience of this “immediate access” paradigm, specifically within the context of thoracic diagnostic procedures.
📊 Methodological Strengths & Weaknesses
- Strengths:
- Patient-Centered Focus: The study addresses a critical gap in the literature regarding the psychological impact of “open notes” and immediate result release in procedural medicine.
- Qualitative/Mixed Methods: By capturing patient perspectives, the authors provide nuance that quantitative data (e.g., portal login rates) cannot capture, highlighting the emotional burden of receiving high-stakes news via a digital interface.
- Weaknesses:
- Selection Bias: As with many survey-based studies, there is a risk of response bias; patients with strong negative or positive experiences are more likely to participate.
- Generalizability: The study likely reflects a specific institutional culture or patient demographic. The impact of immediate access is heavily dependent on the patient’s baseline health literacy and the strength of the pre-procedural counseling provided.
- Lack of Longitudinal Follow-up: The study captures a “snapshot” of the patient’s reaction but does not necessarily measure the long-term impact on the patient-physician trust dynamic or the downstream effect on anxiety levels during the interval between result release and clinical follow-up.
💡 Takeaway for Fellows
- Pre-Procedural Counseling is Paramount: The “immediate access” era makes your pre-procedural discussion more important than ever. You must explicitly tell the patient: “You will see these results in your portal before I call you. If you see words that worry you, please do not panic; wait for our scheduled follow-up to discuss the clinical context.”
- The “Portal Gap”: Be aware that the time between the release of the pathology report and your clinical interpretation is a period of high patient anxiety. If possible, have a system in place (e.g., a nurse navigator or a scheduled follow-up call) to bridge this gap.
- Language Matters: When documenting in the EMR, remember that your notes are now patient-facing. While you must be accurate, consider how your phrasing (e.g., “highly suspicious for malignancy”) will be interpreted by a patient reading it on their phone at 8:00 PM on a Friday.
- Proactive Communication: If you know a biopsy is high-risk for malignancy, consider calling the patient as soon as the preliminary report is available, rather than relying on the portal to do the “heavy lifting.” Your voice remains the most effective tool for mitigating the distress caused by raw data.
Abstract
Keep reading
N opens the next oneClinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
CT-guided fiducial placement remains a relevant technique for pre-procedural localization of peripheral lung lesions.
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.